7 hours Ago By Defense World Staff
Russell Investments Group Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL – Free Report ) by 169.
2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60,021 shares of the company’s stock after buying an additional 37,726 shares during the quarter. Russell Investments Group Ltd.
owned about 0.08% of Zentalis Pharmaceuticals worth $182,000 at the end of the most recent quarter. A number of other institutional investors have also made changes to their positions in ZNTL.
Prudential Financial Inc. bought a new position in Zentalis Pharmaceuticals in the 4th quarter worth approximately $39,000. Ieq Capital LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter worth about $46,000.
Dynamic Technology Lab Private Ltd acquired a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth approximately $53,000. Meriwether Wealth & Planning LLC acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $66,000. Finally, Raymond James Financial Inc.
acquired a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $68,000. Analysts Set New Price Targets A number of brokerages have commented on ZNTL. Wedbush reiterated a “neutral” rating and issued a $4.
00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th.
Wells Fargo & Company decreased their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th.
Finally, UBS Group decreased their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday, January 28th.
Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.24.
Zentalis Pharmaceuticals Price Performance ZNTL opened at $1.43 on Friday. The company has a market capitalization of $102.
69 million, a PE ratio of -0.57 and a beta of 1.80.
The business has a fifty day simple moving average of $1.66 and a 200 day simple moving average of $2.51.
Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.01 and a 1 year high of $13.
24. Zentalis Pharmaceuticals ( NASDAQ:ZNTL – Get Free Report ) last announced its earnings results on Wednesday, March 26th. The company reported ($0.
66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09.
The business had revenue of $26.90 million for the quarter. Equities analysts anticipate that Zentalis Pharmaceuticals, Inc.
will post -2.42 earnings per share for the current fiscal year. Insider Buying and Selling In related news, insider Ingmar Bruns bought 20,000 shares of the business’s stock in a transaction on Thursday, February 6th.
The shares were purchased at an average price of $2.28 per share, for a total transaction of $45,600.00.
Following the completion of the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This represents a 120.
27 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link . Also, Director Jan Skvarka purchased 60,000 shares of the stock in a transaction dated Friday, January 31st.
The shares were bought at an average price of $1.72 per share, with a total value of $103,200.00.
Following the completion of the acquisition, the director now directly owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. This represents a 67.
00 % increase in their position. The disclosure for this purchase can be found here . 3.
60% of the stock is currently owned by company insiders. About Zentalis Pharmaceuticals ( Free Report ) Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Featured Articles Five stocks we like better than Zentalis Pharmaceuticals Most active stocks: Dollar volume vs share volume Short Sellers Gave Up on These 3 Names Recently Top Biotech Stocks: Exploring Innovation Opportunities 3 Boring Stocks Outperforming the Market This Year Most Volatile Stocks, What Investors Need to Know If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
